演化之聲
THE SOUND OF EVOLUTION
Human Gene AtlasHOMO SAPIENS
HUMAN PROTEIN-CODING GENE

SRCASV

SRC proto-oncogene, non-receptor tyrosine kinase

SRC 是非受體型蛋白質酪胺酸激酶,接收多類細胞受體訊號,並藉由磷酸化調節細胞黏附、骨架重組與多種細胞活動。

Homo sapiens20q11.23UniProt P12931
OFFICIAL SYMBOL
SRC
CHROMOSOME
20
UNIPROT
P12931
PDB / ALPHAFOLD
8JN8
01 / GENE OVERVIEW

基因總覽

SRC proto-oncogene, non-receptor tyrosine kinase 是一種蛋白質編碼基因,其產物屬於蛋白質激酶超家族中的酪胺酸激酶家族 SRC 亞家族。SRC 是非受體型酪胺酸激酶,主要作為細胞訊號傳遞中的激酶,能回應多類細胞受體的活化。其蛋白質包含 SH3、SH2 與蛋白質激酶結構域,另有一段位於 N 端的無序區域。這些結構特色與其辨識訊號、參與蛋白質磷酸化的角色相符;具體的作用方式及其在不同細胞過程中的功能,依細胞訊號與底物而異。

Official symbol
SRC
Gene name
SRC proto-oncogene, non-receptor tyrosine kinase
Organism
Homo sapiens
Gene type
Protein coding
HGNC ID
HGNC:11283
UniProt
P12931
02 / NOMENCLATURE

基因異名與舊稱

Alternative gene names & synonyms
ASVc-srcSRC1

異名取自 HGNC,可能包含歷史名稱;蛋白質名稱以 UniProt 註解為準。

03 / GENOMIC CONTEXT

染色體位置與基因結構

Chromosome 2020q11.23
chr20 · 64,444,167 bp · GRCh38chr20p13 · 1–5100000 · gnegchr20p12.3 · 5100001–9200000 · gpos75chr20p12.2 · 9200001–12000000 · gnegchr20p12.1 · 12000001–17900000 · gpos75chr20p11.23 · 17900001–21300000 · gnegchr20p11.22 · 21300001–22300000 · gpos25chr20p11.21 · 22300001–25700000 · gnegchr20p11.1 · 25700001–28100000 · acenchr20q11.1 · 28100001–30400000 · acenchr20q11.21 · 30400001–33500000 · gnegchr20q11.22 · 33500001–35800000 · gpos25chr20q11.23 · 35800001–39000000 · gnegchr20q12 · 39000001–43100000 · gpos75chr20q13.11 · 43100001–43500000 · gnegchr20q13.12 · 43500001–47800000 · gpos25chr20q13.13 · 47800001–51200000 · gnegchr20q13.2 · 51200001–56400000 · gpos75chr20q13.31 · 56400001–57800000 · gnegchr20q13.32 · 57800001–59700000 · gpos50chr20q13.33 · 59700001–64444167 · gnegSRCpq1 bp64,444,167 bp
GRCh38 / 1-based inclusiveDirection: forward strand (+)
Genomic coordinates
chr20:37,344,673–37,406,050
Gene span
61,378 bp
Strand
Forward (+)
Gene assembly
GRCh38
查看實際轉錄本與 exon 註解
TranscriptGenomic coordinatesExons
ENST00000373578 ★37,346,140–37,406,05014
ENST0000087622637,344,673–37,406,05014
ENST0000087622737,344,673–37,406,05013
ENST0000087622837,344,673–37,406,05015
ENST0000087622937,344,673–37,406,05015
ENST0000087623037,345,108–37,406,05014
ENST0000087623137,345,108–37,406,05014
ENST0000069211237,345,213–37,406,05015
ENST0000069301237,345,213–37,387,8016
ENST0000069242337,345,213–37,406,05015
ENST0000087623237,345,213–37,406,05015
ENST0000087623337,345,213–37,406,05013

顯示 12/24 個蛋白質編碼轉錄本;canonical 優先。

帶型與著絲點依 Ensembl 座標繪製;核染色體長度以 GRCh38 第 1 號染色體為共同尺度。黃色標記表示本基因位置,細小區間加粗以利辨識;實際基因長度與 exon 見下方資料。

04 / BIOLOGICAL FUNCTION

分子功能與生物學過程

SRC 是多種細胞受體活化後可啟動的非受體型酪胺酸激酶。受體聚集或二聚化時,SRC 可被招募至受體複合體,並磷酸化受體細胞質區的酪胺酸殘基;它也參與啟動其他蛋白質酪胺酸激酶家族。SRC 的激酶反應以 ATP 作為磷酸基供體,將蛋白質上的酪胺酸磷酸化。SRC 家族成員具有功能冗餘,因此各成員的特定作用不易區分。

在細胞黏附與骨架調節方面,整合素傳遞的細胞外基質訊號會伴隨黏著斑蛋白(包括 PTK2/FAK1 與 PXN)酪胺酸磷酸化。SRC 也作用於細胞間連結的蛋白質,例如黏著連結中的 CTNNB1、CTNND1、JUP,以及間隙連結中的 GJA1。磷酸化 AFAP1 可使 SRC 的 SH2 結構域與 AFAP1 結合,並定位至肌動蛋白絲;CTTN 磷酸化也參與細胞骨架重整,但此項功能標註為可能。SRC 對 PKP3 的磷酸化則可能在活性氧反應下促使其離開橋粒連結並進入細胞質。

SRC 亦參與多種受體下游訊號。它透過磷酸化 RASA1 與 RASGRF1 參與 RAS 路徑,也可參與 PDGF 介導的 STAT1、STAT3 磷酸化,提升這些轉錄因子的 DNA 結合活性。SRC 對 EGFR 內吞有必要作用,涉及磷酸化 clathrin heavy chain;它也參與 beta-arrestin 去敏化,並與 EGF 刺激的 MAPK 級聯有關。部分相關描述標註為可能,或依相似性推定。

在破骨細胞中,SRC 與 PTK2B/PYK2 形成複合體且具激酶活性,對骨吸收功能是必要的。它可被 PTK2B/PYK2 招募至活化的整合素,磷酸化 CBL,進而促進磷脂醯肌醇 3-激酶活化並招募至細胞膜。相對地,G(q) 依賴的 KISS1/KISS1R 訊號可使 SRC 與 DUSP18 一同被招募至 KISS1R C 端;DUSP18 介導 SRC 去磷酸化與失活,並降低破骨細胞分化及活性,抑制骨吸收。

SRC 的其他作用包括增強 RIGI 引發的抗病毒訊號、參與 podosome 形成,以及經 IL6 訊號活化 YAP1-NOTCH 路徑以促進發炎誘發的上皮再生。它也可磷酸化 CASP8,抑制其加工與活化,降低 CASP8 的促細胞凋亡功能。不同異構型的活性與底物偏好並不相同:異構型 2 相較異構型 1 的基礎激酶活性較高,可能與分子內作用減弱、Tyr-419 自體磷酸化增加有關;此異構型對 synaptophysin 與特定 SH3 結合基序胜肽的親和力較低,並可能參與神經突延伸。

05 / GENE REGULATION

Promoter 與基因調控

到

以 TSS = 0 為基準:負數為上游、正數為下游,包含起點與終點。每次最多取得 100,000 bp。

TSS: 37346140 · 正股
依所選 TSS 來源,取得指定上、下游範圍的基因組序列。
擷取區間依所選 TSS 計算;調控註解與實驗支持的 TSS 可在下方查閱。
>SRC ENST00000373578 GRCh38 chr20:37345140-37346240 strand=1 5′→3′
相對 TSS:-1000 到 +100 bp;1101 bp
依轉錄本 TSS 擷取的基因組序列;TSS = 0,兩端包含,未驗證為 promoter
GAGAACTTTCAAAGAAGGAATATGGAGGCAGGTGTGATATTTAAAGCTGGACCCAGGCCCACCTTTCCCT
GTGCTAGGATTCCAGGACAGGTAAGGAGCCAAGGGTGGGGTGCCCAGCCCCAAAAGGATAGCCCTGGAGC
CTGCGCCAGGGGGTAAGAGGGGAGTCTTTGTGGCCTAAAGCAGCATTTCCTCAATGTCCCGTTTTTCTGC
TACATTTCCTGCCCTGGTTCAGAGGTACTTAGCCTCTTTACTTACTTGGAAGTGTGACTGCCACTCAGAT
GCCCTGGTCAGCCCCTCCTAAGCAGTAATAATTAGAACTAGGGGACTTCCGATGGGCTGCCAGGGATGTT
TTGCCCTTATGCACTTAAAATGAACCCGTAACTATTAAAATAAATGTCGCTCCTCCCCACCCTGTCCCTC
CTGCCCCAGCCCCTACTTTGAGAAACTCAGGTCAAGGCTAAAGTCCAAGGCCTGGTTCTTGTCAGTGCCT
CAGTTTCCCCATCTGTAAAGTGGGGCGATCTTCCGCCGCTCAGGCCAGGTGGTGGTTAGGATTAAACCCT
GAAGTCGACCTGAGCAGCTTAGCATGGCGCCTGGCCCAGAGCGGGCGCTCCACGCCCGCTGATATTATTA
CCAATCGTGATTTCGGGAGAGGCGGATCTGGGGCGTAGAAGGTGGGTGGGTTGGGGAGGGCATTTTGGCC
TGGGGGCGGATGGGGCCCGCGGGGTGCGGCGCCCTGGCGGAGTGGGAGGCGGGGCTTCTGTGCCCGGTGT
CCCCACCCCGCCCGGACCCCCAGCTCGGGCCGCCCCTGGGTCTCTCCCGGGTCACCGGCGGGGAATCCGT
CCCCGCGCGCTTCCTCCTTCCTCCTCCTCCCGGCTGCCTGCCGGGCCCCTCCTCCCAGCTCGCGCGCTCC
CTCCCTCCTCTTCCCCTCCCCGGGCCGCCGCCGCCTCCTCCTCCTCCTCCTCCCTTTCTCTCTCGATCTG
TCTCTCCCGGCCCGGAATCCATTCCGGCCTGGGAGCCGGAGCGGCCAGGCCGCCGTCTGCCCGTCCCGCT
GGACGTCCCGCGGTCCGCCCTCCCGTGCGTCCGTCTGCCGGTGAGCCCGCC
SRC 位於正股。上下游依轉錄方向計算,序列一律以該方向的 5′→3′ 顯示;負股會取得反向互補序列。
EPDnew 實驗支持 promoter/TSS · 2 筆
EPDnew IDTSS(1-based)股向來源顯示區間
SRC_1 ↗20:37,344,713正股37,344,664–37,344,723
SRC_2 ↗20:37,383,595正股37,383,546–37,383,605

EPDnew human v006 · UCSC hg38,GRCh38/hg38,透過 UCSC 取得。TSS 具有 CAGE/RAMPAGE 等實驗資料支持;任意擷取的上下游區間仍需另行判讀調控功能,不能視為整段皆經功能驗證。

EPD 封存狀態 ↗ · UCSC 資料說明 ↗ · EPD team, SIB Swiss Institute of Bioinformatics; UCSC Genome Browser · CC BY 4.0

查看已取得的調控/motif 註解

ENSR20_9JS78 · enhancer · 37342699–37343190 · regulatory

ENSR20_B9F4Q · enhancer · 37343587–37344098 · regulatory

ENSR20_7479SD · promoter · 37344099–37344199 · regulatory

ENSR20_B9F4T · enhancer · 37344218–37345219 · regulatory

ENSR20_B9F53 · promoter · 37345619–37346150 · regulatory

ENSR20_C5P3K · enhancer · 37346151–37347393 · regulatory

ENSR20_B9F5D · enhancer · 37347835–37348449 · regulatory

ENSR20_B9F5M · enhancer · 37349569–37350489 · regulatory

ENSR20_747B55 · enhancer · 37350776–37350877 · regulatory

· motif · 37344092–37344103 · motif

· motif · 37345168–37345180 · motif

· motif · 37345490–37345505 · motif

· motif · 37345503–37345523 · motif

· motif · 37345975–37345988 · motif

· motif · 37346073–37346086 · motif

· motif · 37350107–37350120 · motif

· motif · 37350273–37350286 · motif

· motif · 37350273–37350286 · motif

· motif · 37350407–37350419 · motif

目前未取得此類註解。
序列擷取依所選 TSS 與相對範圍計算;該區間的調控功能需參照相應的實驗證據。
06 / PROTEIN ANATOMY

蛋白質結構域與序列

參考蛋白質長度:536 aa

1 aa536 aa結構域功能區域
依 P12931 的 UniProt 殘基座標與蛋白質長度繪製;結構域、DNA 結合區、功能區域與基序分列,重疊註解分行顯示。區域色彩區分類型,並非活性或信心分數。

SRC 蛋白質長 536 個胺基酸,屬於蛋白質激酶超家族的酪胺酸激酶 SRC 亞家族。其註解結構包含 SH3 結構域、SH2 結構域及蛋白質激酶結構域;第 1 至 53 個胺基酸為無序區域。異構型 2 的 SH3 結構域對 SH2 與激酶結構域之間的 linker 序列親和力較低,可能與該異構型較高的基礎激酶活性有關。

結構域SH384–145 aa
結構域SH2151–248 aa
結構域Protein kinase270–523 aa
功能區域Disordered1–53 aa
07 / STRUCTURAL BIOLOGY

蛋白質三維結構

自動載入 · 可拖曳旋轉與縮放
正在載入 PDB · 8JN8…

PDB · 8JN8

X-ray · 1.90 A · A=1-536

查看原始結構紀錄 ↗

實驗模型;依序列位置著色,可能只覆蓋局部區域。

08 / SUBCELLULAR LOCALIZATION

細胞內定位

動物細胞結構與蛋白質定位細胞膜包圍細胞質;細胞核內有核仁,粗面內質網鄰接核膜,粒線體含內膜摺疊,高基氏體由堆疊扁平囊組成。深綠色圓點依來源註解標記定位,器官大小與數量為示意。圓點數量不表示含量;未繪示構造列於圖旁文字。 細胞質 細胞膜 粗面內質網與核糖體 細胞核與核膜 核仁 粒線體:外膜與含摺疊的內膜 高基氏體與運輸囊泡 胞內體、溶體與其他囊泡(示意)
定位:Cell membrane;Mitochondrion inner membrane;Nucleus;Cytoplasm, cytoskeleton;Cytoplasm, perinuclear region;Cell junction, focal adhesion;Cell junction

SRC 可位於細胞膜、粒線體內膜、細胞核、細胞骨架及核周區域,也見於細胞連結與黏著斑。 整合素受刺激後,SRC 會移至黏著斑;此定位需要肉豆蔻醯化及 SH3 結構域。 核周區域的 SRC 可與 PDLIM4 共定位,但兩者不在黏著斑共定位。

深綠色圓點:來源記載的蛋白質定位;數量不表示含量。

未繪示構造:Cell junction, focal adhesion;Cell junction。這些構造未在通用細胞圖中標點,仍保留來源定位名稱。

動物細胞結構示意;器官大小與數量不按比例。點選細胞構造可查看定位註解。

09 / PROTEIN NETWORK

交互作用與訊號網絡

圖中 50 個夥伴 · 最多顯示 50 個
ASVSRCABL1ABL2ACTN1ADAM10ADAM12ADAM15ADRB2AFDNAPBA2ARARRB1ARRB2ASAP1ASCL4BCAR1BECN1CBLCDC37CDCP1CDH1CSNK2A1CTNNB1DLG1DLG2DLG3DLG4EGFRERBB2ERBB3ESR1ETS1FASFBH1FRMPD2FYNGAB1GRB10GRID2IPGRIP1GRIP2HK1HNRNPKHSP90AA1IKBKGIL16KDRKHDRBS1KITKLF15LDB3
來源支持的結構/直接結合關係其他來源關係紀錄

拖曳節點後放開可帶動位置變化;點選夥伴查看證據。位置與連線長度不代表結合強度,圖中未推定夥伴彼此之間的關係。

更多交互作用夥伴 · 已取得 91 個夥伴
第 1 頁

查看 UniProt 完整互作來源 ↗

SRC 可參與由 PTPRA、BCAR1、BCAR3 與 SRC 組成的複合體;其形成依賴整合素介導的 PTPRA 酪胺酸磷酸化。另有多種直接互作,例如 SRC 透過 SH2 結構域辨識磷酸化的 PTK2B/PYK2,並與 RACK1 結合;RACK1 的酪胺酸磷酸化會增強此互作,而該互作可抑制 SRC 活性。KISS1/KISS1R 訊號活化時,SRC 也與 KISS1R 及 DUSP18 互作,且此互作與 SRC 去磷酸化、失活及破骨細胞活性下降有關。感染情境下,SRC 的 SH3 結構域與 HEV ORF3 protein 互作;SH2 結構域則與 HCV non-structural protein 5A 的 N 端互作。

10 / HUMAN HEALTH

疾病與遺傳關聯

SRC 激酶活性曾在若干腫瘤組織及腫瘤細胞株(包括結腸癌細胞)中被觀察到升高;此資料呈現活性與腫瘤的關聯,未表明其因果關係。另一方面,影響 SRC 所代表基因的變異會造成血小板減少症 6(THC6),屬常染色體顯性疾病。患者可能有骨骼異常,且骨髓纖維化風險增加。

個別變異的臨床意義取決於其證據;基因層級的疾病關聯不能套用至所有變異。
11 / CONTEXTUAL FUNCTIONAL EVIDENCE MATRIX

Contextual Functional Evidence Matrix

功能證據與細胞情境矩陣

矩陣以「功能主張」為列,以細胞情境、干預條件、量測結果與證據來源為欄,方便比較同一功能在不同條件下的支持情形。只有含情境與實驗資訊的紀錄會列入矩陣;一般功能註解另列於下方。

11 筆功能證據/註解
目前尚無同時具備實驗情境與干預/量測資訊的證據列。可查核的功能敘述列於「功能註解總覽」,空白實驗欄位不以推測補齊。
功能註解總覽 · 11 筆
功能面向功能敘述證據類型可查核來源
功能SRC 是非受體型酪胺酸激酶,可在免疫受體、整合素及其他黏附受體、受體型酪胺酸激酶、G 蛋白偶聯受體與細胞激素受體等多類受體受刺激後活化。它參與轉錄、免疫、黏附、細胞週期、凋亡、移動與轉化等訊號;受體聚集或二聚化可招募 SRC 磷酸化受體胞質區。其底物與作用包含細胞骨架及細胞連結蛋白、RAS 與 STAT 訊號、EGFR 內吞、破骨細胞骨吸收、抗病毒訊號及上皮再生等;部分作用標示為可能或依相似性推定。SRC 家族功能冗餘使個別成員角色不易界定。含實驗來源
證據與來源

Non-receptor protein tyrosine kinase which is activated following engagement of many different classes of cellular receptors including immune response receptors, integrins and other adhesion receptors, receptor protein tyrosine kinases, G protein-coupled receptors as well as cytokine receptors. Participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. SRC appears to be one of the primary kinases activated following engagement of receptors and plays a role in the activation of other protein tyrosine kinase (PTK) families. Receptor clustering or dimerization leads to recruitment of SRC to the receptor complexes where it phosphorylates the tyrosine residues within the receptor cytoplasmic domains. Plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. Phosphorylation of AFAP1 allows the SRC SH2 domain to bind AFAP1 and to localize to actin filaments. Cytoskeletal reorganization is also controlled through the phosphorylation of cortactin (CTTN) (Probable). When cells adhere via focal adhesions to the extracellular matrix, signals are transmitted by integrins into the cell resulting in tyrosine phosphorylation of a number of focal adhesion proteins, including PTK2/FAK1 and paxillin (PXN). In addition to phosphorylating focal adhesion proteins, SRC is also active at the sites of cell-cell contact adherens junctions and phosphorylates substrates such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP). Another type of cell-cell junction, the gap junction, is also a target for SRC, which phosphorylates connexin-43 (GJA1). SRC is implicated in regulation of pre-mRNA-processing and phosphorylates RNA-binding proteins such as KHDRBS1 (Probable). Phosphorylates PKP3 at 'Tyr-195' in response to reactive oxygen species, which may cause the release of PKP3 from desmosome cell junctions into the cytoplasm. Also plays a role in PDGF-mediated tyrosine phosphorylation of both STAT1 and STAT3, leading to increased DNA binding activity of these transcription factors (By similarity). Involved in the RAS pathway through phosphorylation of RASA1 and RASGRF1. Plays a role in EGF-mediated calcium-activated chloride channel activation. Required for epidermal growth factor receptor (EGFR) internalization through phosphorylation of clathrin heavy chain (CLTC and CLTCL1) at 'Tyr-1477'. Involved in beta-arrestin (ARRB1 and ARRB2) desensitization through phosphorylation and activation of GRK2, leading to beta-arrestin phosphorylation and internalization. Has a critical role in the stimulation of the CDK20/MAPK3 mitogen-activated protein kinase cascade by epidermal growth factor (Probable). Might be involved not only in mediating the transduction of mitogenic signals at the level of the plasma membrane but also in controlling progression through the cell cycle via interaction with regulatory proteins in the nucleus. Plays an important role in osteoclastic bone resorption in conjunction with PTK2B/PYK2. Both the formation of a SRC-PTK2B/PYK2 complex and SRC kinase activity are necessary for this function. Recruited to activated integrins by PTK2B/PYK2, thereby phosphorylating CBL, which in turn induces the activation and recruitment of phosphatidylinositol 3-kinase to the cell membrane in a signaling pathway that is critical for osteoclast function. Upon activation of the G(q)-dependent KISS1/KISS1R signaling pathway, active SRC is recruited, together with the phosphatase DUSP18, to the KISS1R C-terminus. This leads to DUSP18-mediated SRC dephosphorylation and inactivation, down-regulation of osteoclast differentiation and activity, and consequently suppression of bone resorption (By similarity). Promotes energy production in osteoclasts by activating mitochondrial cytochrome C oxidase. Phosphorylates DDR2 on tyrosine residues, thereby promoting its subsequent autophosphorylation. Phosphorylates RUNX3 and COX2 on tyrosine residues, TNK2 on 'Tyr-284' and CBL on 'Tyr-731'. Enhances RIGI-elicited antiviral signaling. Phosphorylates PDPK1 at 'Tyr-9', 'Tyr-373' and 'Tyr-376'. Phosphorylates BCAR1 at 'Tyr-128'. Phosphorylates CBLC at multiple tyrosine residues, phosphorylation at 'Tyr-341' activates CBLC E3 activity. Phosphorylates synaptic vesicle protein synaptophysin (SYP) (By similarity). Involved in anchorage-independent cell growth. Required for podosome formation (By similarity). Mediates IL6 signaling by activating YAP1-NOTCH pathway to induce inflammation-induced epithelial regeneration. Phosphorylates OTUB1, promoting deubiquitination of RPTOR. Phosphorylates caspase CASP8 at 'Tyr-380' which negatively regulates CASP8 processing and activation, down-regulating CASP8 pro-apoptotic function. Mediates laminin-induced activation of RAC1 signaling through phosphorylation of syntrophin (By similarity)

PMID 11389730 ↗ · PMID 12615910 ↗ · PMID 14585963 ↗ · PMID 16186108 ↗ · PMID 16619028 ↗ · PMID 18586953 ↗ · PMID 19307596 ↗ · PMID 19419966 ↗ · PMID 20100835 ↗ · PMID 20525694 ↗ · PMID 21309750 ↗ · PMID 21411625 ↗ · PMID 22710723 ↗ · PMID 25501895 ↗ · PMID 25731159 ↗ · PMID 34234773 ↗ · PMID 35927303 ↗ · PMID 38346942 ↗ · PMID 7853507 ↗ · PMID 8755529 ↗ · PMID 8759729 ↗ · PMID 11964124 ↗ · PMID 8672527 ↗ · PMID 9442882 ↗

開啟資料庫紀錄 ↗

功能SRC 是非受體型蛋白質酪胺酸激酶,對 synaptophysin 具有高親和力,並可使其磷酸化。推論支持
證據與來源

Non-receptor protein tyrosine kinase which phosphorylates synaptophysin with high affinity

開啟資料庫紀錄 ↗

功能相較異構型 1,異構型 2 的基礎激酶活性較高;依相似性推定,分子內作用減弱可能增加 Tyr-419 自體磷酸化與後續活化。其 SH3 結構域對 SH2 與激酶結構域間 linker 的親和力較低,可能解釋活性差異。異構型 2 的底物偏好也不同,對 synaptophysin 及含第一類或第二類 SH3 結合基序的胜肽親和力較弱;它可能位於 L1CAM 下游,參與細胞骨架重整及神經突延伸。推論支持
證據與來源

Non-receptor protein tyrosine kinase which shows higher basal kinase activity than isoform 1, possibly due to weakened intramolecular interactions which enhance autophosphorylation of Tyr-419 and subsequent activation (By similarity). The SH3 domain shows reduced affinity with the linker sequence between the SH2 and kinase domains which may account for the increased basal activity (By similarity). Displays altered substrate specificity compared to isoform 1, showing weak affinity for synaptophysin and for peptide substrates containing class I or class II SH3 domain-binding motifs (By similarity). Plays a role in L1CAM-mediated neurite elongation, possibly by acting downstream of L1CAM to drive cytoskeletal rearrangements involved in neurite outgrowth (By similarity)

開啟資料庫紀錄 ↗

功能相較異構型 1,異構型 2 的基礎激酶活性較高;依相似性推定,分子內作用減弱可能增加 Tyr-419 自體磷酸化與後續活化。其 SH3 結構域對 SH2 與激酶結構域間 linker 的親和力較低,可能解釋活性差異。此異構型底物偏好改變,對 synaptophysin 及含第一類或第二類 SH3 結合基序的胜肽親和力較弱,並可能參與神經突延伸。推論支持
證據與來源

Non-receptor protein tyrosine kinase which shows higher basal kinase activity than isoform 1, possibly due to weakened intramolecular interactions which enhance autophosphorylation of Tyr-419 and subsequent activation (By similarity). The SH3 domain shows reduced affinity with the linker sequence between the SH2 and kinase domains which may account for the increased basal activity (By similarity). Displays altered substrate specificity compared to isoform 1, showing weak affinity for synaptophysin and for peptide substrates containing class I or class II SH3 domain-binding motifs (By similarity). Plays a role in neurite elongation (By similarity)

開啟資料庫紀錄 ↗

分子活性L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+)含實驗來源
證據與來源

L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+)

PMID 14632929 ↗ · PMID 19307596 ↗ · PMID 21036157 ↗ · PMID 25501895 ↗ · PMID 34234773 ↗ · PMID 35927303 ↗ · PMID 7929427 ↗ · PMID 8759729 ↗ · PMID 9571170 ↗

開啟資料庫紀錄 ↗

交互作用SRC 可與多種蛋白質互作,也參與特定複合體。PTPRA、BCAR1、BCAR3 與 SRC 複合體的形成依賴整合素介導的 PTPRA 酪胺酸磷酸化。SRC 可透過 SH2 或 SH3 等結構域辨識特定互作對象;例如與磷酸化 PTK2B/PYK2、RACK1、KISS1R 及 DUSP18 互作。RACK1 磷酸化可增強其與 SRC 的結合並抑制 SRC 活性;KISS1/KISS1R 訊號誘發的 KISS1R、DUSP18 互作則與 SRC 去磷酸化失活及骨吸收下降相關。SRC 亦與多種受體、訊號蛋白及細胞骨架相關蛋白互作。含實驗來源
證據與來源

Part of a complex comprised of PTPRA, BCAR1, BCAR3 (via SH2 domain) and SRC; the formation of the complex is dependent on integrin mediated-tyrosine phosphorylation of PTPRA. Interacts with DDEF1/ASAP1; via the SH3 domain (By similarity). Interacts with CCPG1 (By similarity). Identified in a complex containing FGFR4, NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN (By similarity). Interacts with ERBB2, STAT1 and PNN (By similarity). Interacts with DDR1, DDR2 and DAB2 (By similarity). Interacts with CDCP1, TGFB1I1 and TOM1L2. Interacts with the cytoplasmic domain of MUC1, phosphorylates it and increases binding of MUC1 with beta-catenin. Interacts with RALGPS1; via the SH3 domain. Interacts with CAV2 (tyrosine phosphorylated form). Interacts (via the SH3 domain and the protein kinase domain) with ARRB1; the interaction is independent of the phosphorylation state of SRC C-terminus (By similarity). Interacts with ARRB1 and ARRB2. Interacts with SRCIN1. Interacts with NDFIP2 and more weakly with NDFIP1. Interacts with PIK3CA and/or PIK3C2B, PTK2/FAK1 and ESR1 (dimethylated on arginine). Interacts with FASLG. Interacts (via SH2 domain) with the 'Tyr-402' phosphorylated form of PTK2B/PYK2. Interacts (via SH2 domain) with FLT3 (tyrosine phosphorylated) (By similarity). Interacts with PDGFRA (tyrosine phosphorylated) (By similarity). Interacts with CSF1R (By similarity). Interacts (via SH2 and SH3 domain) with TNK2. Interacts (via protein kinase domain) with the tyrosine phosphorylated form of RUNX3 (via runt domain). Interacts with TRAF3 (via RING-type zinc finger domain). Interacts with RIGI, MAVS and TBK1. Interacts (via SH2 domain) with RACK1; the interaction is enhanced by tyrosine phosphorylation of RACK1 and inhibits SRC activity. Interacts with EPHB1; activates the MAPK/ERK cascade to regulate cell migration. Interacts with FCAMR. Interacts (via SH2 domain) with the 'Tyr-9' phosphorylated form of PDPK1. Interacts with AMOTL2; this interaction regulates the translocation of phosphorylated SRC to peripheral cell-matrix adhesion sites. Interacts with TRAP1. Interacts with CBLC; the interaction is enhanced when SRC is phosphorylated at Tyr-419. Interacts with ARHGEF5 (By similarity). Interacts (via cytoplasmic domain) with CEACAM1 (via SH2 domain); this interaction is regulated by trans-homophilic cell adhesion. Interacts with MPP2. Interacts with PRR7. Interacts (via kinase domain and to a lesser extent the SH2 domain) directly with PDLIM4; this interaction results in PTPN13-mediated dephosphorylation of this protein leading to its inactivation. Interacts with P85 (PIK3R1 or PIK3R2). Interacts with HNRNPA2B1. Interacts with IL6ST/gp130. Interacts (via SH3 domain) with PELP1 in the presence of 17-beta-estradiol. Interacts with AMBRA1 (By similarity). Interacts with KISS1R and DUSP18; the interaction depends on activation of KISS1/KISS1R signaling pathway. Interaction with KISS1R and DUSP18 is required for SRC dephosphorylation and inactivation, and down-regulation of osteoclast activity and bone resorption (By similarity)

PMID 10747847 ↗ · PMID 10753943 ↗ · PMID 11152665 ↗ · PMID 11279199 ↗ · PMID 12091389 ↗ · PMID 12925710 ↗ · PMID 14585963 ↗ · PMID 14661060 ↗ · PMID 14963108 ↗ · PMID 15504032 ↗ · PMID 15851033 ↗ · PMID 16479011 ↗ · PMID 17202804 ↗ · PMID 17293535 ↗ · PMID 17525734 ↗ · PMID 18024423 ↗ · PMID 18657504 ↗ · PMID 19307596 ↗ · PMID 19419966 ↗ · PMID 19665017 ↗ · PMID 19807924 ↗ · PMID 20100835 ↗ · PMID 20534535 ↗ · PMID 21309750 ↗ · PMID 21411625 ↗ · PMID 22801373 ↗ · PMID 22888118 ↗ · PMID 23564345 ↗

開啟資料庫紀錄 ↗

交互作用在微生物感染情境下,SRC 會透過 SH3 結構域與 HEV ORF3 protein 互作。含實驗來源
證據與來源

(Microbial infection) Interacts with HEV ORF3 protein; via the SH3 domain

PMID 11518702 ↗

開啟資料庫紀錄 ↗

交互作用在微生物感染情境下,SRC 會透過 SH2 結構域與 HCV non-structural protein 5A 互作;互作區域位於該病毒蛋白的 N 端。含實驗來源
證據與來源

(Microbial infection) Interacts (via SH2 domain) with HCV non-structural protein 5A (via N-terminus)

PMID 30862675 ↗

開啟資料庫紀錄 ↗

細胞定位SRC 位於細胞膜、粒線體內膜、細胞核、細胞骨架、核周區域及細胞連結等位置。整合素受刺激後,SRC 會定位至黏著斑;此定位需要肉豆蔻醯化與 SH3 結構域。SRC 與 PDLIM4 在核周區域共定位,但在黏著斑不共定位。含實驗來源
證據與來源

Cell membrane / Lipid-anchor; Mitochondrion inner membrane; Nucleus; Cytoplasm, cytoskeleton; Cytoplasm, perinuclear region; Cell junction, focal adhesion; Cell junction; Localizes to focal adhesion sites following integrin engagement. Localization to focal adhesion sites requires myristoylation and the SH3 domain. Colocalizes with PDLIM4 at the perinuclear region, but not at focal adhesions

PMID 7525268 ↗ · PMID 22801373 ↗ · PMID 12615910 ↗ · PMID 7853507 ↗ · PMID 19307596 ↗ · PMID 22294297 ↗

開啟資料庫紀錄 ↗

疾病關聯SRC 激酶活性曾被觀察到在若干腫瘤組織與腫瘤細胞株中升高,例子包括結腸癌細胞。這項資料描述活性升高與腫瘤的關聯,並未指出該變化造成腫瘤。含實驗來源
證據與來源

SRC kinase activity has been shown to be increased in several tumor tissues and tumor cell lines such as colon carcinoma cells

PMID 2498394 ↗ · PMID 3093483 ↗

開啟資料庫紀錄 ↗

疾病關聯影響 SRC 所代表基因的變異會造成血小板減少症 6(THC6),此病為常染色體顯性遺傳的血液疾病,特徵是循環血液中的血小板數量降低,可能增加出血並降低凝血能力。患者也可能出現骨骼異常,且骨髓纖維化風險增加。含實驗來源
證據與來源

Thrombocytopenia 6 THC6 A form of thrombocytopenia, a hematologic disorder defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. THC6 is an autosomal dominant form. Affected individuals may also have bone abnormalities and an increased risk for myelofibrosis. The disease is caused by variants affecting the gene represented in this entry MIM: 616937

PMID 26936507 ↗

開啟資料庫紀錄 ↗

情境矩陣 0 筆 · 一般功能註解 11 筆。互作清單與機器格式紀錄不列入本區。
證據分項判讀,不加總為單一可信度分數。「含實驗來源」依資料庫證據標記辨識;未逐篇核對原始方法的紀錄,不宣稱已完成實驗審查。
12 / SEQUENCE EXPLORER

核酸與蛋白質序列

完整轉錄本 · UTR / CDS 著色 · FASTA
ENST00000373578 · 4,644 nt · GRCh38
依 Ensembl exon 註解拼接的 GRCh38 參考序列,保留非編碼區。
1ATTCCGGCCTGGGAGCCGGAGCGGCCAGGCCGCCGTCTGC40
41CCGTCCCGCTGGACGTCCCGCGGTCCGCCCTCCCGTGCGT80
81CCGTCTGCCGGTGAGCCCGCCCGCCCGCCGGCCCAGAACA120
121GAGAACAGAAGCTCAGAGAAGTGAAGCAACTTGCCCAGCT160
161ATGAGAGACAGAGCCAGGATTTGAAACCAGATGAGGACGC200
201TGAGGCCCAGAGAGGGAAAGCCACTTGCCTAGGGACACAC240
241AGCGGGGAGAGGTGGAGCAGGGCCTCTATTTCGAGACCCC280
281TGACTCCACACCTGGTGTTTGTGCCAAGACCCCAGGCTGC320
321CTCCCAGGTCCTCTGGGACAGCCCCTGCCTTCTACCAGGA360
361CCATGGGTAGCAACAAGAGCAAGCCCAAGGATGCCAGCCA400
401GCGGCGCCGCAGCCTGGAGCCCGCCGAGAACGTGCACGGC440
441GCTGGCGGGGGCGCTTTCCCCGCCTCGCAGACCCCCAGCA480
481AGCCAGCCTCGGCCGACGGCCACCGCGGCCCCAGCGCGGC520
521CTTCGCCCCCGCGGCCGCCGAGCCCAAGCTGTTCGGAGGC560
561TTCAACTCCTCGGACACCGTCACCTCCCCGCAGAGGGCGG600
601GCCCGCTGGCCGGTGGAGTGACCACCTTTGTGGCCCTCTA640
641TGACTATGAGTCTAGGACGGAGACAGACCTGTCCTTCAAG680
681AAAGGCGAGCGGCTCCAGATTGTCAACAACACAGAGGGAG720
721ACTGGTGGCTGGCCCACTCGCTCAGCACAGGACAGACAGG760
761CTACATCCCCAGCAACTACGTGGCGCCCTCCGACTCCATC800
801CAGGCTGAGGAGTGGTATTTTGGCAAGATCACCAGACGGG840
841AGTCAGAGCGGTTACTGCTCAATGCAGAGAACCCGAGAGG880
881GACCTTCCTCGTGCGAGAAAGTGAGACCACGAAAGGTGCC920
921TACTGCCTCTCAGTGTCTGACTTCGACAACGCCAAGGGCC960

cDNA 使用 DNA 字母 T;mRNA 模式改以 U 顯示。轉錄本保留已註解的非編碼區,未另外加入 poly(A) 尾;非編碼 RNA 的參考轉錄本也可能仍需後續加工。數字為所選序列的 1-based 位置。長序列以黃色捲軸瀏覽,可複製或下載完整轉錄本與蛋白質;基因組 DNA 隨捲動取得所需範圍。